The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.

 
Web www.patentalert.com

< N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators

> Hypolipidemic and/or hypocholesteremic compounds obtainable from the goldenseal plant

~ 00436